Skip to main content

Advertisement

SpringerLink
Log in

Difference in characteristics and lesion reactivation between type 3 macular neovascularization with and without subretinal fluid at baseline

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the characteristics and incidence rates of lesion reactivation after anti-vascular endothelial growth factor (VEGF) treatment in type 3 macular neovascularization (MNV) with and without subretinal fluid (SRF) at baseline.

Methods

This retrospective study included 95 patients diagnosed with type 3 MNV. After the initial loading injections, re-treatment was performed when lesion reactivation occurred defined as the re-accumulation of subretinal or intraretinal fluid or the new development of a retinal/subretinal hemorrhage. The differences in the baseline characteristics and the incidence rates of lesion reactivation were compared between patients with SRF (SRF group, n = 42) and those without SRF (non-SRF group, n = 53).

Results

At diagnosis, the mean visual acuity was worse (0.68 ± 0.41 vs 0.50 ± 0.36; P = 0.032), mean central retinal thickness was greater (515.4 ± 145.9 μm vs 383.8 ± 105.5 μm; P < 0.001), and the incidence of focal retinal hemorrhages was higher (90.5% vs 66.0%; P = 0.005) in the SRF group than in the non-SRF group. In the SRF group, the first lesion reactivation was noted in 89.7% at a mean of 5.8 ± 4.4 months after the third injection. In the non-SRF group, the first lesion reactivation was noted in 70.6% at a mean of 6.1 ± 3.8 months. There was a significant difference in lesion reactivation between the two groups (P = 0.019).

Conclusions

The difference in the baseline characteristics and incidence of lesion reactivation between type 3 MNV with and without SRF suggests that the presence of SRF may be indicative of more advanced disease with a high risk of visual deterioration. This result also suggests the need for more active treatment to preserve vision in patients with SRF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chaudhary V, Matonti F, Zarranz-Ventura J, Stewart MW (2022) Impact of fluid compartments on functional outcomes for patients with neovascular age-related macular degeneration: a systematic literature review. Retina 42:589–606

    Article  Google Scholar 

  2. Sacconi R, Forte P, Tombolini B, Grosso D, Fantaguzzi F, Pina A, Querques L, Bandello F, Querques G (2022) OCT predictors of 3-year visual outcome for type 3 macular neovascularization. Ophthalmol Retina 6:586–594

    Article  Google Scholar 

  3. Kim JH, Kim JW, Kim CG (2022) Difference between the incidence of retinal fluid subtypes and their association with visual outcomes according to the types of macular neovascularization in a Korean population. J Ocul Pharmacol Ther 38:261–268

    Article  CAS  Google Scholar 

  4. Sharma A, Cheung CMG, Arias-Barquet L, Ozdek S, Parachuri N, Kumar N, Hilely A, Zur D, Loewenstein A, Vella G, Bandello F, Querques G (2022) Fluid-based visual prognostication in type 3 macular neovascularization-flip-3 study. Retina 42:107–113

    CAS  Google Scholar 

  5. Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, Matsumoto Y, Sorenson JA, Yannuzzi L (2008) Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 28:201–211

    Article  Google Scholar 

  6. Yannuzzi LA, Negrão S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N (2012) Retinal angiomatous proliferation in age–related macular degeneration 2001. Retina 32(Suppl 1):416–434

    Article  Google Scholar 

  7. Su D, Lin S, Phasukkijwatana N, Chen X, Tan A, Freund KB, Sarraf D (2016) An updated staging system of type 3 neovascularization using spectral domain optical coherence tomography. Retina 36(Suppl 1):S40–S49

    Article  Google Scholar 

  8. Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo C, Chakravarthy U (2021) Fluid-based prognostication in n-AMD: type 3 macular neovascularisation needs an analysis in isolation. Br J Ophthalmol 105:297–298

    Article  Google Scholar 

  9. Nagiel A, Sarraf D, Sadda SR, Spaide RF, Jung JJ, Bhavsar KV, Ameri H, Querques G, Freund KB (2015) Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography. Retina 35:638–647

    Article  Google Scholar 

  10. Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2019) Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment. Graefes Arch Clin Exp Ophthalmol 257:1183–1189

    Article  CAS  Google Scholar 

  11. Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2019) Age-related differences in the prevalence of subtypes of neovascular age-related macular degeneration in the first diagnosed eye. Graefes Arch Clin Exp Ophthalmol 257:891–898

    Article  Google Scholar 

  12. Tsai ASH, Cheung N, Gan ATL, Jaffe GJ, Sivaprasad S, Wong TY, Cheung CMG (2017) Retinal angiomatous proliferation. Surv Ophthalmol 62:462–492

    Article  Google Scholar 

  13. Kim JH, Chang YS, Kim JW, Kim CG, Lee DW, Kim HS (2019) Long-term visual changes in initially stronger fellow eyes in patients with unilateral type 3 neovascularization. Retina 39:1672–1681

    Article  Google Scholar 

  14. Invernizzi A, Teo K, Nguyen V, Daniell M, Squirrell D, Barthelmes D, Gillies MC (2019) Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months. Br J Ophthalmol 103:1337–1341

    Article  Google Scholar 

  15. Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ, Toth CA, Hagstrom SA, Maguire MG, Martin DF (2017) Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmol 124:97–104

    Article  Google Scholar 

  16. Kim JH, Kim JW, Kim CG, Lee DW (2020) Long-term treatment outcomes in type 3 neovascularization: focus on the difference in outcomes between geographic atrophy and fibrotic scarring. J Clin Mid 9:1145

    Article  Google Scholar 

  17. Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Mones J, Regillo C, Tadayoni R, Talks J, Wolf S (2015) Treat-and-extend regimens with anti-vegf agents in retinal diseases: a literature review and consensus recommendations. Retina 35:1489–1506

    Article  CAS  Google Scholar 

  18. Haj Najeeb B, Deak G, Schmidt-Erfurth U, Gerendas BS (2020) The RAP STUDY, REPORT TWO: the regional distribution of macular neovascularization type 3, a novel insight into its etiology. Retina 40:2255–2262

    Article  Google Scholar 

  19. Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2020) Characteristics of type 3 neovascularization lesions: focus on the incidence of multifocal lesions and the distribution of lesion location. Retina 40:1124–1131

    Article  Google Scholar 

  20. Rosenberg D, Deonarain DM, Gould J, Sothivannan A, Phillips MR, Sarohia GS, Sivaprasad S, Wykoff CC, Cheung CMG, Sarraf D, Bakri SJ, Chaudhary V (2022) Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). https://doi.org/10.1038/s41433-022-02020-7

  21. Arias L, Cervera E, Vilimelis JC, Escobar JJ, Escobar AG, Zapata M (2020) Efficacy and safety of a treat-and-extend regimen with aflibercept in treatment-naive patients with type 3 neovascularization: a 52-week, single-arm, multicenter trial. Retina 40:1234–1244

    Article  CAS  Google Scholar 

  22. Shin JY, Yu HG (2014) Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients. Retina 34:2359–2366

    Article  CAS  Google Scholar 

  23. Engelbert M, Zweifel SA, Freund KB (2009) “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 29:1424–1431

    Article  Google Scholar 

  24. McBain VA, Kumari R, Townend J, Lois N (2011) Geographic atrophy in retinal angiomatous proliferation. Retina 31:1043–1052

    Article  Google Scholar 

  25. Sadda SR, Guymer R, Monés JM, Tufail A, Jaffe GJ (2020) Anti-vascular endothelial growth factor use and atrophy in neovascular age-related macular degeneration: systematic literature review and expert opinion. Ophthalmol 127:648–659

    Article  Google Scholar 

  26. Kim JH, Lee TG, Kim JW, Kim CG, Cho SW, Han JI (2014) Small retinal haemorrhages accompanied by macular soft drusen: prevalence, and funduscopic and angiographic characteristics. Br J Ophthalmol 98:1066–1072

    Article  Google Scholar 

  27. Spaide RF (2019) New proposal for the pathophysiology of type 3 neovascularization as based on multimodal imaging findings. Retina 39:1451–1464

    Article  CAS  Google Scholar 

Download references

Funding

Kim’s Eye Hospital Research Center (Seoul, South Korea) provided funding for English editing support. The sponsor had no role in the design or conduct of the study.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Kim’s Eye Hospital, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, Seoul, 150-034, South Korea

    Jae Hui Kim, Jong Woo Kim & Chul Gu Kim

Authors
  1. Jae Hui Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jong Woo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chul Gu Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jae Hui Kim.

Ethics declarations

Ethical approval

This study was approved by the Institutional Review Board of Kim’s Eye Hospital (Seoul, South Korea) and conducted in accordance with the tenets of the Declaration of Helsinki.

Informed consent

Informed consent was not obtained as no participant information was identified in this study.

Conflict of interest

The authors declare no competing interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, J.H., Kim, J.W. & Kim, C.G. Difference in characteristics and lesion reactivation between type 3 macular neovascularization with and without subretinal fluid at baseline. Graefes Arch Clin Exp Ophthalmol 261, 401–408 (2023). https://doi.org/10.1007/s00417-022-05833-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-022-05833-0

Keywords

Search

Navigation